Natco Pharma
Natco Pharma Share Price Chart
Natco Pharma last traded at ₹800.10 (2026-10-13). Over the past month the stock moved -2.3%, three months the stock moved -32.6%, year the stock moved -9.6%. Its closing range over 52 weeks is ₹790.00 – ₹1,197.70, with the latest close 33.2% below the high.
Closing prices up to 2026-10-13.
About Natco Pharma
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. [1] NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.[2]
Business Segments[1] a) Pharmaceuticals (97% in FY26 vs 99% in FY25): i) Export Formulation: [2] [3] [4] The company manufactures and markets finished dosage formulations in 50+ countries, including the US, Canada, Brazil, and Europe, etc. It is ranked among the top 10 generic companies in sales in Canada. Its Major US partners include Sun Pharma, Alvogen, Teva, Mylan, Actavis, Lupin, Breckenridge Pharmaceuticals, and Dr. Reddy’s. Its international business focuses on Para IV filings, and it plans to expand into emerging markets like MENA, ASEAN, and LATAM.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Natco Pharma reported sales of ₹735.00 crore (-44.7%) and net profit of ₹206.00 crore (-57.1%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 735.00 | 186.00 | 25.00 | 206.00 | 11.53 |
| Mar 2026 | 739.00 | 128.00 | 17.00 | 269.00 | 14.96 |
| Dec 2025 | 647.00 | 159.00 | 25.00 | 151.00 | 8.46 |
| Sep 2025 | 1,363 | 579.00 | 42.00 | 518.00 | 28.94 |
| Jun 2025 | 1,329 | 571.00 | 43.00 | 480.00 | 26.84 |
| Mar 2025 | 1,221 | 548.00 | 45.00 | 406.00 | 22.70 |
| Dec 2024 | 475.00 | 39.00 | 8.00 | 132.00 | 7.43 |
| Sep 2024 | 1,371 | 804.00 | 59.00 | 676.00 | 37.81 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +33.0% | -37.4% | +14.3% | -2.5% | -0.6% | +36.2% | -39.5% | -44.7% |
| Operating profit growth | +75.5% | -85.4% | +10.3% | -29.1% | -28.0% | +307.7% | -76.6% | -67.4% |
| Net profit growth | +83.2% | -38.0% | +5.2% | -28.1% | -23.4% | +14.4% | -33.7% | -57.1% |
| EPS growth | +83.5% | -37.5% | +5.2% | -28.1% | -23.5% | +13.9% | -34.1% | -57.0% |
| OPM % | 59.0% | 8.0% | 45.0% | 43.0% | 42.0% | 25.0% | 17.0% | 25.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Natco Pharma reported sales of ₹4,078.00 crore (-7.9%) and net profit of ₹1,418.00 crore (-24.7%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 4,078 | 1,436 | 35.00 | 1,418 | 79.20 |
| Mar 2025 | 4,430 | 2,196 | 50.00 | 1,883 | 105.26 |
| Mar 2024 | 3,999 | 1,754 | 44.00 | 1,388 | 77.51 |
| Mar 2023 | 2,707 | 936.00 | 35.00 | 715.00 | 39.18 |
| Mar 2022 | 1,945 | 264.00 | 14.00 | 170.00 | 9.31 |
| Mar 2021 | 2,052 | 606.00 | 30.00 | 442.00 | 24.18 |
| Mar 2020 | 1,915 | 583.00 | 30.00 | 458.00 | 25.31 |
| Mar 2019 | 2,094 | 795.00 | 38.00 | 642.00 | 35.24 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -4.2% | -8.5% | +7.2% | -5.2% | +39.2% | +47.7% | +10.8% | -7.9% |
| Operating profit growth | -14.3% | -26.7% | +3.9% | -56.4% | +254.5% | +87.4% | +25.2% | -34.6% |
| Net profit growth | -7.6% | -28.7% | -3.5% | -61.5% | +320.6% | +94.1% | +35.7% | -24.7% |
| EPS growth | -6.6% | -28.2% | -4.5% | -61.5% | +320.8% | +97.8% | +35.8% | -24.8% |
| OPM % | 38.0% | 30.0% | 30.0% | 14.0% | 35.0% | 44.0% | 50.0% | 35.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
Natco Pharma trades at ₹1186.7, up 50.35% YTD and near 52W highs, with strong technical momentum (Tech Score 78.3, RSI 55, bullish trend). Fundamentals are exceptionally strong: TTM EPS of ₹86.94 with P/E of 13.53 (70% discount to industry median of 45.99), ROE of 18% and ROCE of 33% (both excellent), and OPM averaging 41% across TTM. However, Dec 2025 quarter showed material sequential contraction—sales halved to ₹647Cr from ₹1363Cr in Sep 2025, and net profit fell 71% to ₹151Cr—signaling potential Q4 seasonal weakness or one-off headwinds that warrant near-term caution despite strong fundamentals.
- Exceptional valuation: P/E 13.53 vs industry 45.99 (70% discount), with TTM EPS ₹86.94 and ROE 18%, ROE ROCE 33% signaling high-quality earnings and capital efficiency
- Strong cash generation: TTM OCF ₹1697Cr (139% of net profit), indicating high earnings quality and capex-backed growth investment
- Dominant operating margins: TTM OPM 41% with three consecutive quarters (Sep–Mar 2025) at 42–45%, indicating pricing power and operational leverage despite Q4 seasonal dip
- Q4 FY2025 earnings cliff: Sales halved from ₹1363Cr (Sep) to ₹647Cr (Dec), net profit fell 71% to ₹151Cr, suggesting either aggressive seasonal pattern or unforeseen operational disruption requiring clarification
- Regulatory and pricing pressure: NPPA demand notice (₹4.92Cr) and agrochemical demerger execution risk (March 24 board decision) may create near-term overhang and margin compression on regulated products
AI-generated analysis for informational purposes only — not SEBI-registered investment advice.
See Full AI Analysis — Free FREE →Latest News
-
Natco Pharma Hikes Investment in US-Based eGenesis to USD 16.7 Mn
-
Natco Pharma Board Approves Rights Issue To Raise Up to Rs 1,279 Crore
-
Natco Pharma Board Approves Rights Issue To Raise Up to Rs 1,279 Crore
-
Natco Pharma files FY26 annual report, schedules AGM for September 30 - scanx.trade
-
Natco Pharma stock falls 1.5% as company raises eGenesis investment to $22 million - Moneycontrol.com
-
Natco Pharma to further invest USD 14M in eGenesis Inc. - Business Standard
-
Natco Pharma hosts investor meet in Mumbai and Hong Kong on August 27 - scanx.trade
-
USFDA completes inspection at Natco Pharma’s FDF manufacturing plant in Visakhapatnam
-
NATCO Pharma: What’s the Bigger Strategy Behind Its 49% Adcock Ingram Stake in Africa? - Trade Brains
-
USFDA completes inspection at Natco Pharma’s FDF manufacturing plant in Visakhapatnam
Frequently Asked Questions
What is the share price of Natco Pharma today?
Natco Pharma shares were last quoted at ₹800.10 (+1.4% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Natco Pharma?
Natco Pharma has a price-to-earnings (P/E) ratio of 13.15 and a price-to-book (P/B) ratio of 1.61. The industry P/E is 53.33.
What is the 52-week high and low of Natco Pharma?
The 52-week high of Natco Pharma is ₹1,226.10 and the 52-week low is ₹789.30.
What is the market cap of Natco Pharma?
The market capitalisation of Natco Pharma is about ₹15,046.12 crore.
How did Natco Pharma perform in its latest quarterly results?
In the latest quarter (Jun 2026), Natco Pharma reported sales of ₹735.00 crore (-44.7%) and net profit of ₹206.00 crore (-57.1%), compared with the same quarter last year.
Is Natco Pharma a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Natco Pharma has a 3-year ROE of 23.00%, 3-year profit growth of 26.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Natco Pharma?
Promoters hold about 49.41% of Natco Pharma.
Which sector does Natco Pharma belong to?
Natco Pharma belongs to the Pharmaceuticals & Drugs sector.